This article only represents the author's own views.
Talk about getting hit when you’re already down.
Just as it was trying to soothe investors worried about the imminent retirement of its longtime CEO, Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the cancer drug specialist backed by Hong Kong billionaire Li Ka-shing, has been included on a new U.S. blacklist, this one launched by the U.S. securities regulator singling out Chinese companies in danger of delisting.
您已阅读8%（469字），剩余92%（5715字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。